A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Serologic responses in patients with invasive group a streptococcal disease;



Tekijät: Kailankangas, Ville; Gröndahl-Yli-Hannuksela, Kirsi; Vilhonen, Johanna; Rantakokko-Jalava, Kaisu; Seiskari, Tapio; Lönnqvist, Emilia; Oksi, Jarmo; Syrjänen, Jaana; Vuopio, Jaana

Kustantaja: Elsevier BV

Julkaisuvuosi: 2026

Lehti: International Journal of Infectious Diseases

Artikkelin numero: 108891

Vuosikerta: 170

ISSN: 1201-9712

eISSN: 1878-3511

DOI: https://doi.org/10.1016/j.ijid.2026.108891

Julkaisun avoimuus kirjaamishetkellä: Avoimesti saatavilla

Julkaisukanavan avoimuus : Kokonaan avoin julkaisukanava

Verkko-osoite: https://doi.org/10.1016/j.ijid.2026.108891

Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/526943290

Rinnakkaistallenteen lisenssi: CC BY

Rinnakkaistallennetun julkaisun versio: Kustantajan versio


Tiivistelmä
Objective

To investigate kinetics of anti-streptolysin O (ASO) and anti-deoxyribonuclease B (ADB) and an in-house enzyme immunoassay (EIA) for IgG and IgA in acute and convalescent invasive group A Streptococcal (iGAS) infection.

Materials and methods

We recruited iGAS cases from two Finnish hospitals, between 2018 and 2020. Serum was obtained, on average 2 days, (timepoint A), 9 days (timepoint B) and 3 months (timepoint C) from admission. The sera were analyzed for ASO, ADB, and with EIA for IgA and IgG against the causative strain and the three most common emm types in Finland (emm1, emm28, emm89).

Results

Forty-five cases were recruited, with sera available from 42, 35 and 26 at timepoints A, B and C respectively. At timepoint A, 33% were above the upper limit of normal (ULN) for ASO, and 40% for ADB, but 52% for at least one. At timepoint B, 74% were above ULN for ASO, 79% for ADB, and 91% for at least one. EIA results did not differ between the causative and pooled strains except for IgA at timepoint A.

Conclusions

ASO and ADB have utility in iGAS disease with unavailable culture confirmation. EIA results suggest emm type cross-reactivity, with possible vaccine development implications.



Avainsanat:
invasive infection, serology

Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.

Julkaisussa olevat rahoitustiedot: 
This work was supported by Academy of Finland [grant no 308482 to JVu]; Competitive State Research Financing of the Expert Responsibility area of Turku University Hospital [grant no 8TO5/13285 to JVu, 8TO5/11162 to JVi]; Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital [grant no 9U056 to JS]; Maud Kuistila Foundation [grant no 2018-0063F to JVi]; The Finnish Medical Foundation [grant no 2018-2136 to JVi]; Rauno ja Anne Puolimatka Foundation [2017 and 2020 to JVi]; The Finnish Infectious Disease Association [2020 to Jvi].


Last updated on